vTv Therapeutics Inc. (VTVT)

$ 1.19
+0.04 (+3.48%)
Symbol VTVT
Price $ 1.19
Beta -1.744
Volume Avg. 1.88M
Market Cap 0.080B
Shares () -
52 Week Range 1.11-4.75
1y Target Est -
DCF Unlevered VTVT DCF ->
DCF Levered VTVT LDCF ->
ROE 11.53% Buy
ROA -18.87% Sell
Operating Margin -
Debt / Equity -245.90% Sell
P/E -
P/B -3.37 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest VTVT news

Mr. Stephen Holcombe
Nasdaq Global Market

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 52 full-time employees. The firm is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.